Literature DB >> 17702632

Continuous dopaminergic stimulation--from theory to clinical practice.

Angelo Antonini1.   

Abstract

Patients with advanced Parkinson's disease (PD) experience worsening motor fluctuations and dyskinesia. Management options include deep brain stimulation of the subthalamic nucleus (STN-DBS), subcutaneous apomorphine (in combination with oral levodopa) or continuous duodenal levodopa administration. We have used all three therapies at our clinic in Milan and report our experience. Apomorphine infusion reduced daily off time but did not improve dyskinesia; long-term treatment was associated with impulse control disorders. STN-DBS provided motor benefit, but was associated with behavioural changes including attempted suicide. Duodenal levodopa produced significant clinical benefit without behavioural changes and allowed patients to discontinue all other PD medications. Duodenal levodopa should be considered in PD patients with advanced disease.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17702632     DOI: 10.1016/j.parkreldis.2007.06.002

Source DB:  PubMed          Journal:  Parkinsonism Relat Disord        ISSN: 1353-8020            Impact factor:   4.891


  12 in total

1.  Therapeutic options for continuous dopaminergic stimulation in Parkinson's disease.

Authors:  O K Sujith; Carol Lane
Journal:  Ther Adv Neurol Disord       Date:  2009-03       Impact factor: 6.570

Review 2.  What is the best treatment for fluctuating Parkinson's disease: continuous drug delivery or deep brain stimulation of the subthalamic nucleus?

Authors:  Rüdiger Hilker; Angelo Antonini; Per Odin
Journal:  J Neural Transm (Vienna)       Date:  2010-12-25       Impact factor: 3.575

3.  Continuous Transdermal Delivery of L-DOPA Based on a Self-Assembling Nanomicellar System.

Authors:  Amnon C Sintov; Haim V Levy; Igor Greenberg
Journal:  Pharm Res       Date:  2017-04-12       Impact factor: 4.200

4.  Attempted suicide under high dose dopaminergic therapy including apomorphine.

Authors:  Walter Struhal; Michael Guger; Stephanie Hödl; Sok-Chu Ung; Michael Bach; Gerhard Ransmayr
Journal:  Wien Klin Wochenschr       Date:  2012-07-15       Impact factor: 1.704

Review 5.  Management of impulse control disorders in Parkinson's disease: Controversies and future approaches.

Authors:  Michael Samuel; Maria Rodriguez-Oroz; Angelo Antonini; Jonathan M Brotchie; Kallol Ray Chaudhuri; Richard G Brown; Wendy R Galpern; Melissa J Nirenberg; Michael S Okun; Anthony E Lang
Journal:  Mov Disord       Date:  2015-01-21       Impact factor: 10.338

Review 6.  Oral and infusion levodopa-based strategies for managing motor complications in patients with Parkinson's disease.

Authors:  Angelo Antonini; K Ray Chaudhuri; Pablo Martinez-Martin; Per Odin
Journal:  CNS Drugs       Date:  2010-02       Impact factor: 5.749

7.  Continuous dopaminergic stimulation achieved by duodenal levodopa infusion.

Authors:  Per Odin; Erik Wolters; Angelo Antonini
Journal:  Neurol Sci       Date:  2008-12       Impact factor: 3.307

Review 8.  Application of the concept of continuous dopaminergic stimulation for the management of Parkinson's disease.

Authors:  Qing Lv; Baorong Zhang
Journal:  Neurosci Bull       Date:  2013-03-20       Impact factor: 5.203

9.  A Retrospective Evaluation of the Frequency of Impulsive Compulsive Behaviors in Parkinson's Disease Patients Treated with Continuous Waking Day Apomorphine Pumps.

Authors:  Pedro Barbosa; Andrew J Lees; Cathy Magee; Atbin Djamshidian; Thomas T Warner
Journal:  Mov Disord Clin Pract       Date:  2016-08-11

10.  A Systematic Review of Neuromodulation Treatment Effects on Suicidality.

Authors:  Mehmet Utku Kucuker; Ammar G Almorsy; Ayse Irem Sonmez; Anna N Ligezka; Deniz Doruk Camsari; Charles P Lewis; Paul E Croarkin
Journal:  Front Hum Neurosci       Date:  2021-06-25       Impact factor: 3.169

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.